Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Active, not recruiting · Phase 3 · NCT04685135
Conditions: Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $49,266
- U.S. investigators named
- 5
- Sites paid
- 4
- Planned or actual enrollment
- 453
About the trial
- Sponsor
- Mirati Therapeutics Inc.
- Tested
- MRTX849 (drug), Docetaxel (drug)
- Dates
- Started 2021-02-23; completion 2026-10-30
- Results posted
- Yes
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
From ClinicalTrials.gov, last updated 2026-08-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Mirati Therapeutics, Inc. reported $49,266 in research payments for this study in 2025 (5 payments).
Products named: Krazati
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Gaurav Trikha, MD Hematology & Oncology · St Augustine, FL
- Jun Zhang, M.D., PH.D. Medical Oncology · Iowa City, IA
- Harsha A. Ranganath, M.D. Hematology & Oncology · Indianapolis, IN
- Janelle M. Meyer, MD Hematology & Oncology · Salem, OR
- Marcia R. Cruz-correa, MD Gastroenterology · Rio Piedras, PR
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Oncare Alliance, Llc $22,852
- Pan American Center for Oncology Trials Llc $18,246
- Kumc Research Institute, Incorporated $4,180
- Franciscan Alliance Inc $3,989
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.